Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High-dose sequential chemotherapy and rituximab (R-HDS) in HIV-positive patients with relapsed/refractory non-Hodgkin lymphoma
2007-005506-42Phase 2Terminated
- Sponsor
- IRCCS Ospedale San Raffaele
- Start
- Dec 2007
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of rituximab in diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), primary effusion lymphoma (PEL) and 1 more, sponsored by IRCCS Ospedale San Raffaele. Primary endpoints: Incidence of infectious complications and Mortality after R-HDS. Started Dec 2007; status: terminated.
02
Drugs
rituximab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)follicular lymphoma (FL)primary effusion lymphoma (PEL)human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on 2007-005506-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-005506-42.